In addition to being diagnosed more frequently in older patients, pulmonary arterial hypertension (PAH) is more frequently ...

UCLA scientists discovered that squamous cell skin cancer resists treatment by adapting its metabolism, switching from ...

Mosliciguat, an inhaled once-daily PH medication, can reduce the resistance against blood flow in lung blood vessels, a Phase ...

In The Lancet Respiratory Medicine, Olivier Sitbon and colleagues1 present the results of a randomised, phase 2b clinical trial (ELEVATE-2) that compared the safety and efficacy of pulmonary arterial ...

BACKGROUND: The European Chronic Thromboembolic Pulmonary Hypertension registry (CTEPH), conducted between 2007 and 2012, reported the major impact of pulmonary endarterectomy (PEA) on the long-term ...

In addition, prolonged aortic blood supply to the left pulmonary artery may result in increased pulmonary artery resistance and slower pulmonary blood flow, increasing the risk of thrombosis in the ...

Roivant Sciences Ltd. (NASDAQ:ROIV) created Pulmovant to in-license from Bayer AG (OTC:BAYRY) exclusive worldwide rights to ...

The main pathological features of CTD-PAH are thickening of intima, media and adventitia of pulmonary arterioles, increased pulmonary vascular resistance, autoimmune activation and inflammatory ...

Under an in-license agreement worth up to $294 million, Roivant Sciences gains exclusive worldwide rights from Bayer to ...

Patients with pulmonary arterial hypertension who received bilateral lung or heart-lung transplants showed similar survival ...

What Is a Pulmonary Embolism? A pulmonary embolism (PE) happens when a blood clot suddenly blocks an artery that supplies blood to your lungs. Pulmonary embolism happens when a blood clot travels ...

At ERS 2024, experts debated systemic thrombolysis vs mechanical and surgical treatments for high-risk pulmonary embolism, ...